Stifel Bullish On Sotheby's Despite Legal RisksMark Melin
In light of activist hedge fund Third Point’s legal action in regards to questioning the legality of Sotheby's (NYSE:BID) poison pill measure, Stifel Nicolaus reiterated their Buy rating and $65 price target.
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible